Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Biomea Fusion in a note issued to investors on Friday, January 13th. HC Wainwright analyst J. Pantginis expects that the company will earn ($2.50) per share for the year. HC Wainwright has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($2.74) per share.

Biomea Fusion (NASDAQ:BMEA – Get Rating) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.13).

Biomea Fusion Stock Performance

Shares of NASDAQ:BMEA opened at $7.44 on Monday. Biomea Fusion has a one year low of $2.84 and a one year high of $14.20. The stock has a fifty day moving average of $7.59 and a 200-day moving average of $9.85. The company has a market capitalization of $218.71 million, a PE ratio of -3.05 and a beta of -1.85.

Insider Activity

In other Biomea Fusion news, Director Michael J.M. Hitchcock bought 5,000 shares of Biomea Fusion stock in a transaction dated Monday, November 14th. The stock was bought at an average price of $7.93 per share, for a total transaction of $39,650.00. Following the completion of the acquisition, the director now directly owns 5,000 shares of the company's stock, valued at $39,650. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 45.70% of the company's stock.

Institutional Trading of Biomea Fusion

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Biomea Fusion by 2.0% in the first quarter. BlackRock Inc. now owns 1,705,442 shares of the company's stock valued at $7,606,000 after purchasing an additional 32,634 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Biomea Fusion by 18.5% during the third quarter. Vanguard Group Inc. now owns 803,118 shares of the company's stock worth $7,854,000 after acquiring an additional 125,311 shares in the last quarter. Laurion Capital Management LP raised its holdings in shares of Biomea Fusion by 2.2% during the third quarter. Laurion Capital Management LP now owns 429,400 shares of the company's stock worth $4,200,000 after acquiring an additional 9,251 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Biomea Fusion by 540.5% during the second quarter. Citadel Advisors LLC now owns 335,191 shares of the company's stock worth $4,016,000 after acquiring an additional 282,855 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Biomea Fusion by 1,475.9% during the second quarter. JPMorgan Chase & Co. now owns 273,925 shares of the company's stock worth $3,281,000 after acquiring an additional 256,543 shares in the last quarter. Hedge funds and other institutional investors own 50.28% of the company's stock.

About Biomea Fusion

(Get Rating)

Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.

See Also

• Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
• General Electric Stock, The Sum of All Parts Strategy is Paying Off
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why

Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.